Discover

RDY
Dr. Reddy's Laboratories Limited
13.99
1300 x undefined
3200 x undefined
bid
ask
-
0.50
3.45%
2250 @ 04:00 PM
14.02 +0.03 (0.21%)
Ytd-0.36%
1y-6.36%
13.95
day range
14.43
12.19
52 week range
15.67
Open14.34Prev Close14.49Low13.95High14.43Mkt Cap11.65B
Vol3.00MAvg Vol2.59MEPS0.55P/E25.44Forward P/E20.94
Beta0.26Short Ratio14.70Inst. Own15.28%Dividend0.08Div Yield0.58
Ex Div Date07-09Earning07-2250-d Avg13.58200-d Avg13.861yr Est14.17
Earning
DateForEstimateReportedSurprisesurprise %
2026-05-082026-030.09N/AN/AN/A
2026-01-212025-120.160.16N/AN/A
2025-10-242025-090.180.190.015.56%
2025-07-232025-060.180.20.0211.11%
2025-05-092025-030.20.220.0210.00%
2025-01-232024-120.20.2N/AN/A
Upgrade / Downgrade
DateFirmActionFromTo
2025-06-05HSBCUpgradeHoldBuy
2024-11-06BarclaysUpgradeOverweightOverweight
2024-07-30BarclaysUpgradeOverweightOverweight
2024-05-08BarclaysUpgradeOverweightOverweight
2024-01-29BarclaysUpgradeOverweightOverweight
2023-06-01BarclaysUpgradeOverweightOverweight
Profile
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Institution Ownership
Report DateOrganizationPositionValuePercentage
2026-03-30Robeco Institutional Asset Management B.V.17.18M240.32M2.06%
2026-03-30Blackrock Inc.11.59M162.10M1.39%
2026-03-30Royal Bank of Canada9.98M139.68M1.20%
2026-03-30Morgan Stanley9.37M131.11M1.12%
2026-03-30Aikya Investment Management Ltd8.00M111.92M0.96%
2026-03-30Renaissance Technologies, LLC7.86M109.96M0.94%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-04-29iShares, Inc.-iShares Core MSCI Emerging Markets ETF5.94M83.07M0.71%
2026-04-29-AB Emerging Markets Opportunities ETF3.15M44.02M0.38%
2026-04-29VANGUARD WHITEHALL FUNDS-Vanguard Global Minimum Volatility Fund1.79M25.11M0.22%
2026-04-29VANGUARD Intl Eqy. INDEX Fd.S-Vanguard Emerging Markets Stock Index Fd1.87M26.22M0.22%
2026-05-30American Century ETF Trust-Avantis Emerging Markets Equity ETF1.72M24.00M0.21%
2026-05-30SPDR INDEX SHARES Fd.S-State Street SPDR PORT. Emerging Markets ETF1.48M20.77M0.18%
Dividend
DividendDate
0.0642572026-07-24
0.0642572026-07-09
0.0914852025-07-25
0.476152024-07-30
0.4876692023-07-28
0.4882023-07-07
Split
SplitDate
5 : 12024-11-05
2 : 12006-09-07